Developments in systemic immunomodulatory therapy for psoriasis

Current Opinion in Pharmacology

Volumn 7, Issue 4, 2007, Pages 434-444

  Berger, Emily M ^a   Gottlieb, Alice B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIFUNGAL AGENT; AZATHIOPRINE; CALCIUM CHANNEL BLOCKING AGENT; CHLORAMPHENICOL; COTRIMOXAZOLE; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; FOLIC ACID; IMMUNOMODULATING AGENT; INFLIXIMAB; MACROLIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN DERIVATIVE; PHENYTOIN; PLACEBO; PROBENECID; PSORALEN; RETINOID; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE; THEOPHYLLINE; UNINDEXED DRUG;

ACCIDENTAL INJURY; ALOPECIA; ANEMIA; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTHROPATHY; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER; CHEILITIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; DERMATOLOGY; DISEASE SEVERITY; DRUG ABSORPTION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; GINGIVA HYPERTROPHY; GLOMERULUS FILTRATION RATE; HAIR LOSS; HEPATITIS; HISTOPLASMOSIS; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPESTHESIA; IMMUNOMODULATION; INFECTION; INJECTION SITE CONTUSION; INJECTION SITE REACTION; LEUKOPENIA; LIPID BLOOD LEVEL; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LYMPHOMA; MEDICAL SPECIALIST; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; NEPHROTOXICITY; OFF LABEL DRUG USE; OPTIC NEURITIS; PARESTHESIA; PATHOGENESIS; PERIORBITAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SKIN CANCER; SKIN INFLAMMATION; THROMBOCYTOPENIA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CELL ADHESION MOLECULES; CYTOKINES; DRUG MONITORING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548126864     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.06.002     Document Type: Review

References (56)

1. Callen J.P., Krueger G.G., Lebwohl M., McBurney E.I., Mease P., Menter A., Paller A.S., Pariser D.M., Weinblatt M., and Zimmerman G. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 49 (2003) 897-899
2. ® (methotrexate) [full prescribing information]. Cranbury, NJ: STADA Pharmaceuticals, Inc.; 2005.
3. Roenigk Jr. H.H., Auerbach R., Maibach H., Weinstein G., and Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38 (1998) 478-485
4. Sigmundsdottir H., Johnston A., Gudjonsson J.E., Bjarnason B., and Valdimarsson H. Methotrexate markedly reduces the expression of vascular E-selectin, cutaneous lymphocyte-associated antigen and the numbers of mononuclear leucocytes in psoriatic skin. Exp Dermatol 13 (2004) 426-434
5. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Ludviksson B.R., and Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114 (2005) 154-163
6. Salim A., Tan E., Ilchyshyn A., and Berth-Jones J. Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 154 (2006) 1169-1174
7. ® (cyclosporine) [full prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2005.
8. Gottlieb A.B. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 4 (2005) 19-34
9. Griffiths C.E., Dubertret L., Ellis C.N., Finlay A.Y., Finzi A.F., Ho V.C., Johnston A., Katsambas A., Lison A.E., Naeyaert J.M., et al. Cyclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 150 (2004) S11-S23
10. Ellis C.N., Fradin M.S., Messana J.M., Brown M.D., Siegel M.T., Hartley A.H., Rocher L.L., Wheeler S., Hamilton T.A., Parish T.G., et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 324 (1991) 277-284
11. ® (acitretin) [product information]. Palo Alto, CA: Connetics Corp.; 2004.
12. Nagpal S., Thacher S.M., Patel S., Friant S., Malhotra M., Shafer J., Krasinski G., Asano A.T., Teng M., Duvic M., and Chandraratna R.A. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ 7 (1996) 1783-1791
13. Young H.S., Summers A.M., Read I.R., Fairhurst D.A., Plant D.J., Campalani E., Smith C.H., Barker J.N., Detmar M.J., Brenchley P.E., and Griffiths C.E. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 126 (2006) 453-459
14. Goldfarb M.T., Ellis C.N., Gupta A.K., Tincoff T., Hamilton T.A., and Voorhees J.J. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol 18 (1988) 655-662
15. Lebwohl M., Drake L., Menter A., Koo J., Gottlieb A.B., Zanolli M., Young M., and McClelland P. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 45 (2001) 544-553
16. ® (mycophenolate mofetil) [complete product information]. Nutley, NJ: Roche Laboratories, Inc.; 2005.
17. ®) for psoriasis: a two-center, prospective, open-label clinical trial. J Cutan Med Surg 7 (2003) 193-197
18. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46 (2002) 1-23
19. ® (alefacept) [full prescribing information]. Cambridge, MA: Biogen Idec, Inc.; 2005.
20. Krueger G.G., et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47 (2002) 821-833
21. Lebwohl M., et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 (2003) 719-727
22. Gottlieb A.B., Casale T.B., Frankel E., Goffe B., Lowe N., Ochs H.D., Roberts J.L., Washenik K., Vaishnaw A.K., and Gordon K.B. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 49 (2003) 816-825
23. Goffe B., Papp K., Gratton D., Krueger G.G., Darif M., Lee S., Bozic C., Sweetser M.T., and Ticho B. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 27 (2005) 1912-1921
24. Gottlieb A.B., Boehncke W.H., and Darif M. Safety and efficacy of alefacept in elderly patients and other special populations. J Drugs Dermatol 4 (2005) 718-724
25. ® (efalizumab) [full prescribing information]. San Francisco, CA: Genentech, Inc.; 2005.
26. Gottlieb A.B., Miller B., Lowe N., Shapiro W., Hudson C., Bright R., Ling M., Magee A., McCall C.O., Rist T., et al. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 7 (2003) 198-207
27. Vugmeyster Y., Kikuchi T., Lowes M.A., Chamian F., Kagen M., Gilleaudeau P., Lee E., Howell K., Bodary S., Dummer W., and Krueger J.G. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 113 (2004) 38-46
28. Gottlieb A.B., et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 54 (2006) S154-S163
29. Gordon K.B., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
30. Lebwohl M., et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 349 (2003) 2004-2013
31. Leonardi C.L., et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 52 (2005) 425-433
32. ®) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155 (2006) 170-181
33. Gottlieb A.B. Clinical research helps elucidate the role of tumor necrosis factor-alpha in the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes. Lupus 12 (2003) 190-194
34. Gottlieb A.B., Chamian F., Masud S., Cardinale I., Abello M.V., Lowes M.A., Chen F., Magliocco M., and Krueger J.G. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 175 (2005) 2721-2729. This analysis of skin biopsies taken from psoriasis patients receiving etanercept in a clinical trial advanced our understanding of the mechanism of TNF-blocking therapies in psoriasis. Researchers demonstrated that multiple cell types and inflammatory mediators are decreased by TNF inhibition, and thus TNF influences a myriad cells and mediators to orchestrate psoriasis pathogenesis. They found down-regulation of dendritic cells and of mediators expressed from dendritic cells, thus demonstrating that dendritic cells are important therapeutic targets that may bridge the gap between innate immunity and adaptive immunity in psoriasis.
35. Lizzul P.F., Aphale A., Malaviya R., Sun Y., Masud S., Dombrovskiy V., and Gottlieb A.B. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 124 (2005) 1275-1283
36. Papp K.A., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005) 1304-1312. This is one of the phase III clinical trials of etanercept that included dose reduction from 50 mg SC twice a week to 50 mg SC weekly. Of note, this is the indicated dosing regimen for psoriasis.
37. Leonardi C.L., et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349 (2003) 2014-2022
38. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35. In this phase III study, etanercept significantly reduced symptoms of fatigue and depression in psoriasis patients. There seems to be an association between TNF, fatigue, and depression, although more research is needed to demonstrate a direct relationship between TNF and psychiatric symptoms in psoriasis patients.
39. Gottlieb A.B., Masud S., Ramamurthi R., Abdulghani A., Romano P., Chaudhari U., Dooley L.T., Fasanmade A.A., and Wagner C.L. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe Psoriasis vulgaris. J Am Acad Dermatol 48 (2003) 68-75
40. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
41. Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D., Bala M., Marano C.W., and Menter A. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 51 (2004) 534-542
42. Reich K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374. This pivotal phase III trial demonstrated significant improvements in moderate to severe psoriasis with the administration of induction and maintenance regimens of infliximab. Improvements in nail psoriasis were also demonstrated.
43. ® (etanercept) [full prescribing information]. Thousand Oaks, CA: Amgen and Wyeth Pharmaceuticals, Immunex Corporation; 2005.
44. Moore A., Gordon K.B., Kang S., Gottlieb A., Freundlich B., Xia H.A., and Stevens S.R. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 56 (2007) 598-603
45. ® (infliximab), [full prescribing information]. Malvern, PA: Centocor, Inc.; 2006.
46. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., Li S., Dooley L.T., Arnold C., and Gottlieb A.B. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56 (2007) e1-e15 10.1016/j.jaad.2006.07.017 [online]
47. ® (adalimumab) [full prescribing information]. North Chicago, IL: Abbott Laboratories; 2006.
48. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285. This meta-analysis pooled data from several clinical trials of patients with rheumatoid arthritis and demonstrated that the anti-TNF antibodies adalimumab and infliximab were associated with an increased risk for serious infection and malignancies in the included studies. Note that these data do not include etanercept clinical trials.
49. Okada S.K., and Siegel J.N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis [letter to the editor]. JAMA 296 (2006) 2201-2202
50. Moreland L.W., Weinblatt M.E., Keystone E.C., Kremer J.M., Martin R.W., Schiff M.H., Whitmore J.B., and White B.W. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 33 (2006) 854-861
51. Gelfand J.M., Shin D.B., Neimann A.L., Wang X., Margolis D.J., and Troxel A.B. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 (2006) 2194-2201
52. Chakravarty E.F., Michaud K., and Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 32 (2005) 2130-2135
53. Nijsten T., Margolis D.J., Feldman S.R., Rolstad T., and Stern R.S. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 52 (2005) 434-444
54. Heydendael V.M., Spuls P.I., Opmeer B.C., de Borgie C.A., Reitsma J.B., Goldschmidt W.F., Bossuyt P.M., Bos J.D., and de Rie M.A. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 349 (2003) 658-665
55. Smith C.H., Anstey A.V., Barker J.N., Burden A.D., Chalmers R.J., Chandler D., Finlay A.Y., Grifitths C.E., Jackson K., McHugh N.J., et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153 (2005) 486-497
56. Chalmers R.J., Kirby B., Smith A., Burrows P., Little R., Horan M., Hextall J.M., Smith C.H., Klaber M., and Rogers S. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 152 (2005) 444-450